Bloodstream infection testing market analysis with growth drivers
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Blood Stream Infection Testing Market From 2026 To 2030?
The blood stream infection testing market has seen significant expansion in recent years. It is projected to increase from $8.49 billion in 2025 to $9.5 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.9%. The market’s past growth is primarily linked to the increasing occurrence of bloodstream infections, a rise in hospital-acquired infection rates, the expansion of clinical microbiology laboratories, the adoption of automated diagnostic instruments, and heightened awareness of sepsis management.
The blood stream infection testing market size is anticipated to undergo significant expansion in the foreseeable future. Its value is projected to reach $14.71 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.6%. The expansion during the forecast period is primarily driven by the increasing demand for rapid diagnostic turnaround times, the rising adoption of molecular diagnostics in hospitals, the widening scope of personalized infection management, growing investments in advanced laboratory infrastructure, and the increasing integration of AI-assisted diagnostic tools. Major trends expected in this period include the increasing adoption of rapid molecular diagnostic assays, the rising use of automated blood culture systems, the growing integration of antimicrobial susceptibility testing, the expansion of multiplex pathogen detection panels, and an enhanced focus on early sepsis diagnosis.
Access Your Free Sample Report For In-Depth Market Analysis:
What Significant Factors Are Influencing The Blood Stream Infection Testing Market Expansion?
The future growth of the blood stream infection testing market is expected to be propelled by the increasing prevalence of infectious diseases. These illnesses are defined as conditions caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. The rates of infectious diseases are escalating due to several factors, including increased global travel, urbanization, climate change, antibiotic resistance, and deficiencies in vaccination coverage. Bloodstream infection testing is vital in managing infectious diseases, as it aids in diagnosing and identifying the pathogens responsible for sepsis and other severe infections, thus enabling precise and effective treatment. For instance, in October 2024, the World Health Organization, a Switzerland-based international public health organization, indicated that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, which was an increase from about 7.5 million in 2022, thereby identifying tuberculosis as the leading infectious disease killer. Consequently, the rising occurrence of infectious diseases is significantly driving the blood stream infection testing market.
Which Segments Define The Blood Stream Infection Testing Market Segment Structure?
The blood stream infection testing market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Sample Type: Whole Blood, Blood Culture
3) By Technology: Polymerase Chain Reaction (PCR), Mass Spectroscopy, In Situ Hybridization, Other Technologies
4) By End-User: Hospitals And Diagnostic Centers, Laboratory Service Providers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Instruments: Blood Culture Systems, Automated Microbial Identification Systems, Molecular Diagnostic Instruments
2) By Reagents And Consumables: Blood Culture Media, Antimicrobial Susceptibility Testing Reagents, Nucleic Acid Extraction Kits
3) By Software And Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Maintenance And Support Services
What Trends Are Affecting The Direction Of The Blood Stream Infection Testing Market?
Leading enterprises in the blood stream infection testing market are concentrating on integrating advanced technologies, specifically host-response diagnostics utilizing machine learning, to improve quick detection, bolster clinical decision support, and potentially enhance patient care. These host-response diagnostics examine a patient’s immune system by analyzing gene expression signatures in blood samples through artificial intelligence (AI)-derived algorithms, which helps deduce infection presence, type, and probable severity in real time, thus enabling clinicians to make more rapid and precise treatment decisions. For example, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, obtained clearance from the US Food and Drug Administration for TriVerity. This machine-learning-based molecular blood test is designed to assist in the swift evaluation of patients with suspected acute infections or sepsis. It measures 29 immune-related mRNAs and generates AI-driven scores that indicate the likelihood of bacterial infection, viral infection, and the risk of severe illness, with results aimed to be ready in approximately 30 minutes. TriVerity aids clinical decision-making by decreasing diagnostic ambiguity, facilitating timely targeted therapy, and contributing to the optimization of hospital resource utilization when utilized in conjunction with standard clinical evaluation and laboratory findings.
Who Are The Established Players Within The Blood Stream Infection Testing Market?
Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.
Get The Full Blood Stream Infection Testing Market Report:
Where Is The Blood Stream Infection Testing Market Primarily Concentrated By Region?
North America was the largest region in the blood stream infection testing market in 2025. The regions covered in the blood stream infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Blood Stream Infection Testing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Blood Stream Infection Testing Market 2026, By The Business Research Company
Preoperative Infection Prevention And Wound Cleansing Devices Market Report 2026
Infection Control Supplies Market Report 2026
https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report
Urinary Tract Infection Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
